Compare CECO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | TRVI |
|---|---|---|
| Founded | 1966 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2019 |
| Metric | CECO | TRVI |
|---|---|---|
| Price | $59.51 | $14.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $47.50 | $20.59 |
| AVG Volume (30 Days) | 302.2K | ★ 2.3M |
| Earning Date | 10-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 334.15 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $718,253,000.00 | N/A |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $41.72 | ★ N/A |
| Revenue Growth | ★ 29.86 | N/A |
| 52 Week Low | $17.57 | $2.36 |
| 52 Week High | $59.95 | $14.39 |
| Indicator | CECO | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 71.31 | 70.22 |
| Support Level | $54.27 | $12.85 |
| Resistance Level | $56.60 | $14.00 |
| Average True Range (ATR) | 2.25 | 0.85 |
| MACD | 0.79 | 0.08 |
| Stochastic Oscillator | 95.33 | 91.22 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.